Therefore, the 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/NFSA) Joint Committee for Clinical Practice [22], as well as a position paper from the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and Japanese Heart Failure Society [18], clearly outlined the value of using NT-proBNP as an HF diagnosis instrument HF in patients with dyspnea, as well as a monitoring instrument for establishing HF prognosis in hospitalized patients (both are level IA recommendations). The gene discussed is NPPB; the disease is heart failure.